

Fig. 1. The number and area of GST-P-positive foci in rats given BNF after DEN initiation. Each graph shows the area (a) and number (b) of GST-P positive foci in the liver of rats administered 0 (DEN alone), 0.03%, 0.06%, 0.125% and 0.25% BNF. Column represents mean + S.D. *, ** significantly different from the DEN alone group at $P < 0.05$ or $P < 0.01$, respectively.



Fig. 2. Immunohistochemical photographs of COX-2 in the liver of rats given BNF after DEN initiation. Each photograph shows COX-2-positive cells in the liver of rats administered DEN alone (a) and 0.25% BNF (b). Original magnification × 200 (bar; 200 μm)

the major enzymes involved in the activation of most of the procarcinogens and promutagens (Guengerich and Shimada, 1991; Puntarulo and Cederbaum, 1998). The upregulation of CYP1A1 and 1A2 isoforms indirectly results in the production of a very large amount of ROS (Puntarulo and Cederbaum, 1998; Nishikawa *et al.*, 2002). Therefore, the upregulation of *Cyp1a1* by BNF treatment could have increased the amounts of ROS byproducts due to microsomal oxidation. On the other hand, the detoxification/antioxidant genes including *Akr7a3* and *Gstm1* significantly increased in the groups given 0.125% BNF or more, and *Gpx2* and *Yc2* significantly increased in the groups given 0.06% BNF or more and 0.25% BNF, respectively. These detoxification/antioxidant genes regulated by Nrf2, which is a transcriptional factor, are induced by the activation of Nrf2 by oxidative/electrophile stress (Köhle and Bock, 2007). Our previous study has shown that indole-3-carbinol (I3C) induced hepatocellular tumor promotion in parallel with the induction ratio of *Cyp1a1* and subsequent oxidative stress responses in rats (Shimamoto *et al.*, 2011). In the present study, the GST-P-positive foci increased in the 0.25% BNF together with the induction of *Cyp1a1* but not in the groups given 0.125% BNF or less despite of the high induction of *Cyp1a1*. These results suggest that 0.03% BNF or more induces ROS production due to the induction of *Cyp1a1* but 0.25% BNF only has a liver tumor promoting activity. However, microsomal ROS production and TBARS known as markers of oxidative stress were not changed in the BNF treated groups compared to the DEN alone group. Oxida-

Table 4. Real-time RT-PCR analysis of the liver tissues obtained from male F344 rats given BNF for 6 weeks after DEN treatment

Group	DEN alone	DEN+0.03%BNF	DEN+0.06%BNF	DEN+0.125%BNF	DEN+0.25%BNF
Phase I drug metabolizing enzymes					
Cyp1a1	1.04 ± 0.30	579.12 ± 216.81**	1922.87 ± 1055.00	5888.01 ± 994.34**	8670.44 ± 1637.65**
Cyp1a2	1.00 ± 0.10	3.24 ± 1.01**	7.78 ± 2.19*	16.35 ± 2.33**	29.42 ± 8.14*
Cyp1b1	1.09 ± 0.50	6.10 ± 1.39**	15.42 ± 4.86**	137.08 ± 56.92**	521.18 ± 210.40**
Nqo1	1.01 ± 0.14	2.35 ± 1.25**	3.03 ± 1.04**	5.57 ± 0.88**	9.47 ± 3.18**
Ugt1a6	1.03 ± 0.25	0.94 ± 1.78	0.96 ± 0.13	1.39 ± 0.18*	1.88 ± 0.34**
Phase II drug metabolizing enzymes					
Akr7a3	1.02 ± 0.21	1.37 ± 0.56	1.30 ± 0.50	2.45 ± 1.09*	3.24 ± 1.28**
Gstm1	1.04 ± 0.34	1.28 ± 0.50	1.54 ± 0.65	2.78 ± 1.21*	7.01 ± 2.47**
Gpx2	1.06 ± 0.40	1.57 ± 0.48	2.37 ± 0.89*	2.75 ± 0.43**	5.27 ± 1.22**
Yc2	1.02 ± 0.24	1.03 ± 0.30	0.93 ± 0.22	1.11 ± 0.27	1.43 ± 0.44*
Inflammation related genes					
Ccl2	1.11 ± 0.61	1.78 ± 0.67	2.09 ± 1.30	1.89 ± 0.47	2.18 ± 0.71*
Col1a1	1.28 ± 1.17	1.61 ± 1.57	1.51 ± 0.81	1.46 ± 0.42	2.16 ± 1.12
Il6	1.03 ± 0.25	1.68 ± 0.45*	2.12 ± 1.66	1.36 ± 0.34	2.15 ± 1.09
Mmp12	1.11 ± 0.59	0.99 ± 0.26	1.33 ± 0.66	1.35 ± 0.31	2.32 ± 1.13*
Serpine1	11.07 ± 0.47	1.24 ± 0.33	1.62 ± 0.50	1.76 ± 0.71	2.62 ± 1.46*
Cox-2	1.13 ± 0.59	1.86 ± 0.51	1.82 ± 1.04	2.02 ± 0.49	2.83 ± 0.97**
Tnf	1.04 ± 0.29	1.22 ± 0.22	1.44 ± 0.66	1.22 ± 0.24	1.55 ± 0.47
Tgfb2	1.05 ± 0.36	1.12 ± 0.43	0.97 ± 0.26	1.20 ± 0.21	1.45 ± 0.37
Nfkb1	1.01 ± 0.18	0.91 ± 0.13	1.02 ± 0.13	1.02 ± 0.16	1.14 ± 0.12
Nfkbia	1.01 ± 0.17	0.86 ± 0.16	0.74 ± 0.25*	0.64 ± 0.13**	0.67 ± 0.16**
Apoptosis related genes					
Bax	1.02 ± 0.24	1.12 ± 0.32	1.27 ± 0.58	0.90 ± 0.48	1.21 ± 0.29
Bcl-2	1.02 ± 0.21	1.24 ± 0.39	1.47 ± 0.28	1.70 ± 0.32**	2.36 ± 0.61**
Cell proliferation/Cell cycle related genes					
Tp53	1.02 ± 0.23	0.94 ± 0.23	0.82 ± 0.07	0.92 ± 0.20	0.89 ± 0.18
Ccnb1	1.02 ± 0.22	0.71 ± 0.19*	0.63 ± 0.19**	0.69 ± 0.14*	1.33 ± 0.27
Cdkn1a(p21)	1.03 ± 0.27	1.28 ± 0.43	0.76 ± 0.22	0.51 ± 0.11*	0.49 ± 0.26*
Cdkn2b(p15)	1.02 ± 0.25	1.23 ± 0.29	1.40 ± 0.54	1.33 ± 0.12	1.95 ± 0.38**
Cebpa	1.03 ± 0.28	1.00 ± 0.09	1.03 ± 0.19	0.87 ± 0.27	0.98 ± 0.20

DEN: *N*-diethylnitrosamine, BNF: β-naphthoflavone. The data represent mean ± S.D. Values are expressed as group mean fold change over control.
*, ** significantly different from the DEN alone group at $P < 0.05$ or $P < 0.01$, respectively.

tive stress occurs in cells or tissues when the amount of ROS produced exceeds antioxidant potential (Klaunig *et al.*, 1998). Therefore, it can be speculated that the antioxidant potential of these Nrf2-related enzymes exceeds the amount of ROS generation in the groups given 0.25% BNF or less and the ROS produced is accordingly eliminated from these enzymes.

In the present study, *Ccl2*, *Mmp12*, *Serpine1 and Cox-2* significantly increased in the 0.25% BNF group compared with the DEN alone group. These genes are known to be associated with inflammatory responses (Bertola *et al.*, 2010; Cobos-Correa *et al.*, 2009; Shimada *et al.*, 2010). *Tgfb2* induces *Serpine1* (Konrad *et al.*, 2009), and *Nfkb* and *Tnf* regulate the expression of *Ccl2* (Garg and Aggarwal, 2002). In addition, NFKB may regulate the production of prostaglandins (PG) via the COX-2 (Garg and Aggarwal, 2002). In the present study, COX-2-positive cells increased in the 0.25% BNF group compared with the DEN alone group. In the DEN alone group, COX-2-positive cells were observed in the periportal area of the liver. On the other hand, COX-2-positive cells were expressed throughout the liver in BNF treated groups and especially expressed strongly in the periphery of the foci. We thought that COX-2 was expressed in the Kupffer cells and BNF probably increased the number of Kupffer cells. COX-2 may be involved in the early stage of hepatocarcinogenesis, and increased expression of COX-2 in noncancerous liver tissues has been significantly associated with shorter disease-free survival in patients with hepatocellular carcinomas (Cervello and Montalto, 2006). In tumors, overexpression of COX-2 leads to an increase in PG levels, which affect many mechanisms involved in carcinogenesis such as angiogenesis, inhibition of apoptosis, stimulation of cell growth as well as the invasiveness and metastatic potential of tumor cells (Cervello and Montalto, 2006). In our previous study, enzymatically modified isoquercitrin (EMIQ) suppressed the liver tumor-promoting activity of BNF in rats through suppression of COX-2 (Shimada *et al.*, 2010). In addition, Kuwata *et al.* (2011) performed an additional mechanistic study on liver tumor promotion of BNF and clarified that BNF-induced oxidative stress cause single liver cell toxicity, allowing subsequent concomitant apoptosis and regeneration involving inflammatory responses including TNF-signaling, contributing to tumor promotion. Thus, inflammation is considered to be involved in the liver tumor promoting effect of BNF in rats.

Bcl2 is a proto-oncogene in blocking programed cell death rather than promoting proliferation, and a ratio of Bcl2/Bax determines the survival or death of cells following an apoptotic stimulus (Korsmeyer *et al.*, 1993). In addition, Bcl2 prevents oxidative damage to cellular constituents including cell membranes (Korsmeyer *et al.*, 1993). In the present study, the expression of *Bcl2* significantly increased in the groups given 0.125% BNF or more, but the expression of *Bax* was not changed in the BNF treated groups. Therefore, the exact mechanism of upregulated *Bcl2* is not clear, but *Bcl2* may be induced by ROS that was not completely eliminated from the antioxidant enzymes, and up-regulation of *Bcl2* probably leans the balance between cell survival and apoptosis to cell survival.

In cell proliferation activity, PCNA-positive cells were not significantly fluctuated in the BNF treated groups. P21 is an inhibitor of cyclin/cyclin-dependent kinase (CDK) complexes, and p21 induction is mediated by p53 (Roninson, 2002). Decreased expression of p21 protein contributed to the cell proliferation in altered foci and adenomas induced by BNF (Dewa *et al.*, 2009). In our study, the expression of *p21* decreased and the expression of *p53* slightly, but not significantly, decreased in the 0.25% BNF group. On the contrary, the expression of *p15*, one of CDK inhibitors which arrest cells in the G1 phase of the cell cycle, significantly increased in the 0.25% BNF group (Baldi *et al.*, 2011). Therefore, it can be considered that promotion and suppression of cell proliferation concurrently occurred in the highest dose group of BNF, and no marked cell proliferation is therefore induced in the BNF treated groups.

In conclusion, the result of our study showed that 0.25% BNF is the threshold dose for liver tumor promotion. The fact that oxidative stress was not induced in the doses of BNF used in this study while inflammation-related genes were upregulated and COX-2 protein were induced in the 0.25% BNF group strongly suggests that inflammation is involved in the liver tumor promoting effect of BNF in rats.

ACKNOWLEDGMENT

This study was partly supported by a grant in-aid for research on the safety of veterinary drugs in food of animal origin from the Ministry of Health, Labour and Welfare of Japan (H22-shokuhin-ippan-007).

REFERENCES

Asare, G.A., Mossanda, K.S., Kew, M.C., Paterson, A.C., Kahler-Venter, C.P. and Siziba, K. (2006): Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology, **219**, 41-52.

Baldi, A., De Luca, A. and Esposito, V., Campioni, M., Spugnini, E.P. and Citro, G. (2011): Tumor suppressors and cell-cycle proteins in lung cancer. Patholog. Res. Int. Epub 2011 Oct 5.

Bertola, A., Bonnafous, S., Anty, R., Patouraux, S., Saint-Paul, M.C., Iannelli, A., Gugenheim, J., Barr, J., Mato, J.M., Le, Marchand-Brustel, Y., Tran, A. and Gual, P. (2010): Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One., **5**, e13577.

Brown, J.P. and Dietrich, P.S. (1979): Mutagenicity of plant flavonols in the Salmonella/mammalian microsome test: activation of flavonol glycosides by mixed glycosidases from rat cecal bacteria and other sources. Mutat. Res., **66**, 223-240.

Cervello, M. and Montalto, G. (2006): Cyclooxygenases in hepatocellular carcinoma. World J. Gastroenterol., **12**, 5113-5121.

Cobos-Correa, A., Trojanek, J.B., Diemer, S., Mall, M.A. and Schultz, C. (2009): Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation. Nat. Chem. Biol., **5**, 628-630.

Dewa, Y., Nishimura, J., Muguruma, M., Jin, M., Saegusa, Y., Okamura, T., Tasaki, M., Umemura, T. and Mitsumori, K. (2008): Beta-Naphthoflavone enhances oxidative stress responses and the induction of preneoplastic lesions in a diethylnitrosamine-initiated hepatocarcinogenesis model in partially hepatectomized rats. Toxicology, **244**, 179-189.

Dewa, Y., Nishimura, J., Jin, M., Kawai, M., Saegusa, Y., Harada, T., Shibutani, M. and Mitsumori, K. (2009): Molecular expression analysis of beta-naphthoflavone-induced hepatocellular tumors in rats. Toxicol. Pathol., **37**, 446-455.

Garg, A. and Aggarwal, B.B. (2002): Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia., **16**, 1053-1068.

Guengerich, F.P. and Liebler, D.C. (1985): Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol., **14**, 259-307.

Guengerich, F.P. and Shimada, T. (1991): Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol., **4**, 391-407.

Ito, N., Tamano, S. and Shirai, T. (2003): A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals. Cancer Sci., **94**, 3-8.

Klaunig, J.E., Xu, Y., Isenberg, J.S., Bachowski, S., Kolaja, K.L., Jiang, J., Stevenson, D.E. and Walborg, E.F.Jr. (1998): The role of oxidative stress in chemical carcinogenesis. Environ. Health. Perspect., **106**, **Suppl. 1**, 289-295.

Köhle, C. and Bock, K.W. (2007): Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem. Pharmacol., **73**, 1853-1862.

Konrad, L., Scheiber, J.A., Schwarz, L., Schrader, A.J. and Hofmann, R. (2009): TGF-beta1 and TGF-beta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. Regul. Pept., **155**, 28-32.

Korsmeyer, S.J., Shutter, J.R., Veis, D.J., Merry, D.E. and Oltvai, Z.N. (1993): Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol., **4**, 327-332.

Kuwata, K., Shibutani, M., Hayashi, H., Shimamoto, K., Hayashi, S.M., Suzuki, K. and Mitsumori, K. (2011): Concomitant apoptosis and regeneration of liver cells as a mechanism of liver-tumor promotion by β-naphthoflavone involving TNFα-signaling due to oxidative cellular stress in rats. Toxicology, **283**, 8-17.

Lin, P.H., Lin, C.H., Huang, C.C., Chuang, M.C. and Lin, P. (2007): 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines. Toxicol. Lett., **172**, 146-158.

Livak, K.J. and Schmittgen, T.D. (2001): Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods., **25**, 402-408.

Moriya, K., Nakagawa, K., Santa, T., Shintani, Y., Fujie, H., Miyoshi, H., Tsutsumi, T., Miyazawa, T., Ishibashi, K., Horie, T., Imai, K., Todoroki, T., Kimura, S. and Koike, K. (2001): Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res., **61**, 4365-4370.

Nishikawa, T., Wanibuchi, H., Ogawa, M., Kinoshita, A., Morimura, K., Hiroi, T., Funae, Y., Kishida, H., Nakae, D. and Fukushima, S. (2002): Promoting effects of monomethylarsonic acid, dimethylarsinic acid and trimethylarsine oxide on induction of rat liver preneoplastic glutathione S-transferase placental form positive foci: a possible reactive oxygen species mechanism. Int. J. Cancer, **100**, 136-139.

Ohkawa, H., Ohishi, N. and Yagi, K. (1979): Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., **95**, 351-358.

Prochaska, H.J. and Talalay, P. (1988): Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res., **48**, 4776-4782.

Puntarulo, S. and Cederbaum, A.I. (1998): Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic. Biol. Med., **24**, 1324-1330.

Roninson, I.B. (2002): Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett., **179**, 1-14.

Schlezinger, J.J., White, R.D. and Stegeman, J.J. (1999): Oxidative inactivation of cytochrome P-450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1As. Mol. Pharmacol., **56**, 588-597.

Shimada, Y., Dewa, Y., Ichimura, R., Suzuki, T., Mizukami, S., Hayashi, S.M., Shibutani, M. and Mitsumori, K. (2010): Antioxidant enzymatically modified isoquercitrin suppresses the development of liver preneoplastic lesions in rats induced by beta-naphthoflavone. Toxicology, **268**, 213-218.

Shimamoto, K., Dewa, Y., Kemmochi, S., Taniai, E., Hayashi, H., Imaoka, M., Shibutani, M. and Mitsumori, K. (2011): Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats. Arch. Toxicol., **85**, 1159-1166.

Shoda, T., Mitsumori, K., Onodera, H., Toyoda, K., Uneyama, C., Takada, K. and Hirose, M. (2000a): Liver tumor-promoting effect of beta-naphthoflavone, a strong CYP 1A1/2 inducer, and the relationship between CYP 1A1/2 induction and Cx32 decrease in its hepatocarcinogenesis in the rat. Toxicol. Pathol., **28**, 540-547.

Shoda, T., Mitsumori, K., Takahashi, T., Horiuchi, K., Yamazaki, Y., Suzuki, Y., Katsuda, Y., Yokomoto, Y. and Kurumi, M. (2000b): Liver tumor promotion by β-naphthoflavone, a strong CYP 1A1/2 inducer, in a 28 week two-stage rat hepatocarcinogenesis model using diethylnitrosamine as an initiator. J. Toxicol. Pathol., **13**, 37-43.

Trush, M.A. and Kensler, T.W. (1991): An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radic. Biol. Med., **10**, 201-209.

Wiseman, H. and Halliwell, B. (1996): Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J., **313**, 17-29.

Yoshihara, S., Makishima, M., Suzuki, N. and Ohta, S. (2001): Metabolic activation of bisphenol A by rat liver S9 fraction. Toxicol. Sci., **62**, 221-227.

The Journal of Toxicological Sciences (J. Toxicol. Sci.)
Vol.37, No.5, 969-985, 2012

Original Article

Enhanced liver tumor promotion but not liver initiation activity in rats subjected to combined administration of omeprazole and β-naphthoflavone

Hitomi Hayashi[1,2], Eriko Taniai[1,2], Reiko Morita[1,2], Masahiro Hayashi[3], Daichi Nakamura[3], Atsushi Wakita[3], Kazuhiko Suzuki[1], Makoto Shibutani[1] and Kunitoshi Mitsumori[1]

[1]*Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan*
[2]*United Graduate School of Veterinary Science, Gifu University, 1-1 Yanagido, Gifu-shi, Gifu 501-1193, Japan*
[3]*Gotemba Laboratory, Bozo Research Center Inc., 1284 Kamado, Gotemba-shi, Shizuoka 412-0039, Japan*

(Received June 20, 2012; Accepted July 21, 2012)

ABSTRACT — Omeprazole (OPZ) and β-naphthoflavone (BNF) are cytochrome P450 (CYP)1A inducers and have liver tumor promoting effects. In this study, we investigated the co-promoting and co-initiating effects of OPZ and BNF in rats. In Experiment 1, male rats were subjected to partial hepatectomy (PH), and given oral doses of 138 or 276 mg/kg OPZ, 0.125% or 0.25% BNF or 138 mg/kg OPZ+0.125% BNF (n = 9~12) for 6 weeks after N-diethylnitrosamine (DEN) initiation. In Experiment 2, male rats were treated with oral doses of 138 or 276 mg/kg OPZ, 0.03% or 0.06% BNF or 138 mg/kg OPZ+0.03% BNF (n = 11~12) for 9 days starting 1 week before initiating treatment. As an initiating treatment, 2-Amino-3,4-dimethylimidazo[4,5-*f*]quinolone (MeIQx) was orally administered 12 hr after PH. The rats were fed a basal diet for 15 days, followed by a diet containing 0.015% 2-acetylaminofluorene for the next 10 days with a single oral dose of carbon tetrachloride. In Experiment 1, the number and area of glutathione *S*-transferase placental form-positive foci in the OPZ+BNF group were significantly higher than the average values of the High OPZ or the High BNF group. The expression of cyclooxygenase-2 (*Cox-2*) and COX-2 protein in the liver significantly increased in the OPZ+BNF group. In Experiment 2, liver initiation activity was not enhanced by the co-administration of OPZ+BNF. The results of our studies suggest that the co-administration of OPZ and BNF results in synergistic effects in the liver tumor promotion probably owing to increased COX-2 expression, but no modifying effect in the liver initiation activity of MeIQx in rats.

Key words: Omeprazole, β-naphthoflavone, CYP1A inducer, Liver tumor promotion, Rat

INTRODUCTION

Cytochrome P450 (CYP) 1A enzymes can be induced by a range of chemicals in a process mediated through the aryl hydrocarbon receptor (AhR) (Ma and Lu, 2007). Some CYP1A inducers such as 2,3,7,8-tetrachlorodibenzo-dioxin (TCDD) and β-naphthoflavone (BNF) are known to have liver tumor promoting effects in rats and the ability to augment oxidative stress (Kociba *et al.*, 1978; Dewa *et al.*, 2008). It is generally accepted that microsomal electron systems including CYPs and nicotinamide adenine dinucleotide phosphate (NADPH)-CYP reductase, generate reactive oxygen species (ROS) through metabolism, with the subsequent formation of an oxygenated substrate and water (Poulos and Raag, 1992). Although electron transfer is normally a well-coupled process, superoxide and H_2O_2 may be released in the presence of CYP1A inducers that are poorly metabolized.

We have previously demonstrated that some CYP1A inducers such as BNF, indole-3-carbinol and oxfendazole, have liver tumor promoting effects in rats and induce oxidative stress including microsomal ROS generation and thiobarbituric acid-reactive substances (TBARS) production in the liver (Dewa *et al.*, 2008, 2009; Shimamoto *et al.*, 2011a). We have also shown that a proton pump inhibitor, omeprazole (OPZ), which induces *Cyp1a*, also

Correspondence: Hitomi Hayashi (E-mail: hayashih@cc.tuat.ac.jp)

has a liver tumor promoting effect in rats, but oxidative stress is not involved in the mechanism (Hayashi *et al.*, 2012a).

More than 20 mutagenic and carcinogenic heterocyclic amines (HCAs) are produced by cooking or heating meat or fish (Hirata *et al.*, 2008). 2-Amino-3,4-dimethylimidazo[4,5-*f*]quinolone (MeIQx) is one of the major HCAs contained in cooked food consumed by humans (Tsuda *et al.*, 1999), and is thought to be a human liver carcinogen (Lynch *et al.*, 1992). MeIQx is metabolically activated to genotoxic intermediates by CYP1A2-mediated *N*-hydroxylation in the liver followed by *N*-acetyltransferase (NAT)-mediated *O*-esterification (Kato and Yamazoe, 1987; Yanagawa *et al.*, 1994). In our previous study, both OPZ and BNF have been shown to induce *Cyp1a2* expression in the liver of rats (Dewa *et al.*, 2008; Hayashi *et al.*, 2012b). Therefore, we speculated that simultaneous treatment of OPZ and BNF modifies MeIQx metabolism and enhances liver initiation activity in rats.

It has been demonstrated that simultaneous exposure to several chemicals at doses lower than the apparent carcinogenic doses results in marked carcinogenic actions in rats (Hasegawa *et al.*, 1989). In the present, regulatory agency in each country usually sets the acceptable daily intake and maximum residue limit for each chemical in food. However, if simultaneous exposures of plural chemicals enhance their adverse effects and/or initiation activities, we must reconsider the methods of risk evaluation. We think that the evaluation of the effect on combined administration of plural chemicals is beneficial for the risk assessment and risk management of chemicals contained in food. Therefore, we hypothesized that the combined administration of OPZ and BNF: (1) enhances more CYP1A induction resulting in more ROS generation and intensifies the liver tumor promotion effect; or (2) enhances more CYP1A2 induction resulting in more metabolic activation of MeIQx and intensifies the liver initiation effect.

In the present study, we investigated the modifying effect of liver tumor promotion and liver initiation through combined administration of OPZ and BNF in rats, with a particular focus on gene expression and the biochemical events of ROS generation and TBARS production in the liver.

MATERIALS AND METHODS

Chemicals

OPZ (CAS No. 73590-58-6, purity 98%), BNF (CAS No. 6051-87-2, purity 98%), MeIQx (CAS No. 77500-04-0, purity 99%) and carbon tetrachloride (CCl_4; CAS No. 56-23-5, purity 99.5%) were purchased from Wako Pure Chemical Industries (Osaka, Japan). *N*-Diethylnitrosamine (DEN; CAS No. 55-18-5, purity 99%) and 2-acetylaminofluorene (2-AAF; CAS No.53-96-3, purity 98%) were purchased from Tokyo Kasei Kogyo (Tokyo, Japan).

Animals

Five-week-old male F344 rats used in Experiments 1 and 2 were purchased from Japan SLC Inc. (Shizuoka, Japan), maintained in an air-conditioned room with a 12-hr light/dark cycle (room temperature, 23°C ± 3°C; relative humidity, 55 ± 15%), and given free access to a basal diet (Oriental MF; Oriental Yeast, Tokyo, Japan) and tap water. After a 1-week acclimatization period, the animals were used in these experiments. The animals received humane care, in accordance with the Guide for Animal Experimentation of the Tokyo University of Agriculture and Technology.

Experimental designs

Experiment 1

A medium-term liver carcinogenesis bioassay (Ito *et al.*, 2003) was performed according to the following procedure (Fig. 1) to examine the modification of the liver tumor promoting effect by co-administration of OPZ and BNF. All rats were divided into 6 groups. First, all rats were given an intraperitoneal injection of DEN at a dose of 200 mg/kg body weight, followed by treatment with 0 (DEN alone), 138 mg/kg OPZ (Low OPZ) or 276 mg/kg OPZ (High OPZ) by oral gavage once a day, 0.125% BNF (Low BNF) or 0.25% BNF (High BNF) in diet, or 138 mg/kg OPZ + 0.125% BNF (OPZ+BNF) for 6 weeks starting 2 weeks after DEN treatment. Since the threshold tumor promotion dose of BNF and OPZ is 0.25% and 276 mg/kg, respectively (from our previous research), we adopted half of these doses as the low dose and combination dose in the present study (Hayashi *et al.*, 2012a, 2012b). To enhance hepatocellular proliferation, the rats were subjected to two-thirds partial hepatectomy (PH) at 1 week after the BNF/OPZ treatment was started. The food efficiency in each group was measured during the experiment. At the end of the experiment, the rats were euthanized by exsanguination under ether anesthesia and their livers were excised and weighed. The sliced liver samples were fixed in 10% phosphate-buffered formalin for histopathological and immunohistochemical examinations.



Fig. 1. Experimental design of a medium-term liver carcinogenesis bioassay (Experiment 1) and an *in vivo* liver initiation assay (Experiment 2) in rats.

Experiment 2

An *in vivo* 5-week liver initiation assay was performed according to the method described by Tsuda *et al.* (1980). To examine the modification of MeIQx-induced liver tumor initiating effect by co-administration of BNF and OPZ, we modified the duration of this *in vivo* liver initiation assay to 6 weeks. The experimental design is shown in Fig. 1. First, all rats were treated with 0 (MeIQx alone), 138 mg/kg OPZ (Low OPZ) or 276 mg/kg OPZ (High OPZ) by oral gavage once a day, 0.03% BNF (Low BNF) or 0.06% BNF (High BNF), or 138 mg/kg OPZ + 0.03% BNF (OPZ+BNF) for 9 days starting 1 week before initiating treatment. The rationale for the dosage was determined based on the results from our previous studies in which 0.06% BNF induced *Cyp1a1* and *Cyp1a2* expression, being approximately 1923-fold and 8-fold higher than those of the DEN control, and 276 mg/kg OPZ induced *Cyp1a1* and *Cyp1a2* expression, being approximately 1163-fold and 9-fold higher than those of the DEN control group (Hayashi *et al.*, 2012a, 2012b). As an initiation treatment, 50 mg/kg MeIQx was orally administered 12 hr after PH. One day after the initiation, the rats were fed a basal diet for 15 days, followed by a diet containing 0.015% 2-AAF for 10 days to enhance the tumor-promoting effect. Also, to damage their livers, they were orally administered CCl_4 (0.8 ml/kg bw) dissolved in corn oil on day 29. At the end of the experiment, the rats were euthanized by exsanguination under ether anesthesia and their livers were excised and weighed. The sliced liver samples were fixed in 10% phosphate-buffered formalin for histopathological and immunohistochemical examination.

Histopathology and immunohistochemistry

After formalin fixation of the livers in Experiments 1 and 2, the tissues were dehydrated in graded ethanol and embedded in paraffin. Sections were then mounted onto glass slides and were stained with hematoxylin and eosin or were used for immunohistochemistry analysis. For immunohistochemistry, the horseradish peroxidase avidin-biotin complex method with a Vectastain Elite ABC

kit (Vector Laboratories Burlingame, CA, USA) was used. Endogenous peroxidase was inhibited by incubation with freshly prepared 0.3% hydrogen peroxide with methanol for 30 min. The sections were incubated overnight with rabbit polyclonal anti-glutathione *S*-transferase placental form (GST-P) antibody (Medical & Biological Laboratories, Nagoya, Japan; 1:1,000), mouse monoclonal anti-proliferative cell nuclear antigen (PCNA) antibody (DAKO, Glostrup, Denmark; 1:800) and mouse monoclonal anti-cyclooxygenase-2 (COX-2) antibody (BD Biosciences, Tokyo, Japan; 1:250, Experiment 1 only) at 4°C, followed by incubation with a biotinylated secondary antibody for 30 min and with avidin peroxidase conjugate for 30 min at room temperature. The sections were then developed in 0.05% 3, 3'-diaminobenzidine/hydrogen peroxide as the chromogen. For PCNA staining and COX-2 staining, the deparaffinized tissue sections were placed in an antigen-retrieval solution (0.01 M citrate buffer, pH 6.0) for 20 min in a hot bath at 60°C or autoclaved at 121°C for 10 min prior to immunohistochemical staining. After staining, the slides were lightly counterstained with hematoxylin.

The numbers and areas of GST-P-positive foci (≥ 0.2 mm in diameter) and total areas of the liver sections were quantified using WinRoof software (v5.7.2; Mitani Corp., Fukui, Japan). The number of PCNA-positive cells and COX-2-positive cells counted under × 200 magnification, was expressed as a percentage of the total cells or area counted in 20 randomly selected fields (including foci). In both analyses, cranial and caudal parts of the right lateral liver lobe were used.

Definition of zones in the liver

Suzuki *et al.* (2010) showed that the intralobular difference of GST-P-positive foci expression is related to the MeIQx-hepatocarcinogenesis. Therefore, for the determination of intralobular differences of GST-P-positive foci expression in the liver of Experiment 2, we defined the GST-P-positive foci adjacent to Glisson's sheath as zone 1, adjacent to the central vein as zone 3, and adjacent to both Glisson's sheath and the central vein, or not adjacent to either of them, as zone 2, using the method described by Suzuki *et al.* (2010).

cDNA microarray analysis

Total RNA of the liver obtained from Experiment 1 was extracted with an RNeasy Mini Kit (QIAGEN, Hilden, Germany), in accordance with the manufacturer's instructions. Using 10 μg of total RNA from one animal from each of the controls, 138 mg/kg OPZ, 0.125% BNF and 138 mg/kg OPZ+0.125% BNF groups, double-stranded cDNA was synthesized with an Invitrogen Superscript Double-Stranded cDNA Synthesis kit (Invitrogen Corp., CA, USA), in accordance with the manufacturer's protocol. After labeling with Cy3, 6 μg of each of the Cy3-labeled cDNA sample were loaded onto a *Rattus norvegicus* Roche NimbleGen Microarray for Gene Expression (Roche NimbleGen: Euk Expr 385K catalog Arr, 26,739 targets/microarray). Using the robust multiple average normalization method (Irizarry *et al.*, 2003), differentially expressed genes were analyzed. Gene information was retrieved from the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov).

Real-time RT-PCR analysis

Total RNA of the liver obtained from Experiment 1 was extracted with an RNeasy Mini Kit (QIAGEN), in accordance with the manufacturer's instructions. Reverse transcription was carried out with 2 μg RNA for cDNA synthesis using a Thermoscript RT-PCR System kit (Eppendorf Co., Ltd., Tokyo, Japan), in accordance with the manufacturer's protocol. Quantitative real-time RT-PCR with Power SYBR Green PCR Master Mix (Applied Biosystems Japan Ltd., Tokyo, Japan) was performed using a StepOnePlus™ Real-time PCR System (Applied Biosystems Japan Ltd.). The PCR primers (listed in Table 1) were designed using Primer Express software (Version 3.0; Applied Biosystems Japan Ltd.). The amount of target gene expression was normalized to an endogenous reference (actin, beta) and relative to a control was obtained using the $2^{-\Delta\Delta Ct}$ method (Livak and Schmittgen, 2001).

Lipid peroxidation levels

Oxidative lipid peroxidation was estimated using TBARS. Hepatic TBARS levels were determined using the method described by Ohkawa *et al.* (1979) with a slight modification. The liver tissue samples (approximately 50 mg) obtained from Experiment 1 were homogenized in 450 μl of buffer (containing 50 mM Tris-HCl; pH7.4, 1.15% KCl, 0.2 mM EDTA, 0.1 mM dithiothreitol (DTT), 0.1 mM Protease Inhibitor Cocktail and 20% glycerol) using TissueLyser (QIAGEN). Aliquots of 3 mg of liver homogenates were mixed with 0.2 ml of 8.1% sodium dodecyl sulfate and 3 ml of 0.4% thiobarbituric acid in 10% acetic acid (pH 3.5), heated at 95°C for 60 min and then cooled. Each reaction mixture was centrifuged at 4,000 rpm for 10 min after adding 1 ml of distilled water and 5 ml of n-butanol and pyridine (15:1, v/v). The absorbance of the resulting solution was determined spectrophotometrically at 532 nm, using a Synergy HT Multi-Detection Microplate Reader (BioTek, Winooski, VT, USA). The TBARS levels were expressed as the equiva-

Table 1. Primers used for real-time RT-PCR

Accession no.	Gene description	Symbol	Forward primer	Reverse primer
NM_012540	Cytochrome P450, family 1, subfamily am polypeptide 1	*Cyp1a1*	gccttcacatcagccacaga	ttgtgactctaaccacccagaatc
NM_012541	Cytochrome P450, family 1, subfamily am polypeptide 2	*Cyp1a2*	aagcgccggtgcattg	tgcaggaggatggctaagaag
NM_012940	Cytochrome P450, family 1, subfamily b, polypeptide 1	*Cyp1b1*	cttggccattgatcggaaa	caaggcgagcgaagtacaaagt
NM_001198676	Cytochrome P450, family 2, subfamily b, polypeptide 2	*Cyp2b2*	gggacactgaaaaagagtgaagct	aatgccttcgccaagacaaat
NM_022407	Aldehyde dehydrogenase 1 family, member A1	*Aldh1a1*	agtgccccttcggtggat	gctcagtgtactcataaagaccatgttc
NM_031972	Aldehyde dehydrogenase 3 family, member A1	*Aldh3a1*	tggagcctcatcctggcttat	gaatttggaggagtgaggtgaga
NM_017000	NAD(P)H dehydrogenase, quinone 1	*Nqo1*	tccgcccccaacttctg	tctgcgtgggccaataca
NM_001039691	UDP glucuronosyltransferase 1 family, polypeptide A6	*Ugt1a6*	tggctaccccaaaacgatct	ataccatgggaaccggagtgt
NM_001024285	Aryl-hydrocarbon receptor repressor	*Ahrr*	gctgctggagtctctcaatgg	gcccaggtagtccacaattgtt
NM_013215	Aldo-keto reductase family 7, member A3	*Akr7a3*	ccgcttctttgggaatccat	ggcgatgccattgaagtgt
NM_183403	Glutathione peroxidase 2	*Gpx2*	accgatcccaagctcatcat	tctcaaagttccaggacacatctg
NM_001159739	Glutathione S-transferase Yc2 subunit	*Yc2*	aagctgagcagggctgatgt	acaatgcctgggtccatctc
NM_012600.2	Malic enzyme 1, NADP(+)-dependent, cytosolic	*Me1*	cgaccagcaaagctgagtgtt	ctgccgctggcaaagatc
NM_017232	Cyclooxygenase-2	*Cox-2*	ttcgacttttccaggatggaa	gagtgtctttgactgtgggaggat
NM_012620	Serpin peptidase inhibitor, clade E , member 1	*Serpine1*	tggctcagaacaacaagttcaac	ggcagttccaggatgtcgtact
NM_053963	Matrix metallopeptidase 12	*Mmp12*	gcgaggctgacattacgatactt	taaggtaccacctttgccatca
NM_012589	Interleukin 6	*Il6*	cccaccaggaacgaaagtca	cttgcggagagaaacttcatagc
NM_130752	Fibroblast growth factor 21	*Fgf21*	gccaacaaccagatggaactc	tccttaagcagcagctctctga
XM_342346	Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	*Nfkb1*	gaagtacagaggaaacgcaccagaag	ccgccgccgaaactg
NM_001105720	Rattus norvegicus nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha	*Nfkbia*	gcctagccccgagcattc	aatgatctgtttccccaaatttca
NM_012675	Tumor necrosis factor	*Tnf*	acaaggctgccccgactat	ctcctggtatgaagtggcaaatc
NM_053677	Checkpoint kinase 1	*Chek1*	tggcagctggcaaagga	aatcccagtcttccacaaaagg
NM_001012742	Wee 1 homolog (S. pombe)	*Wee1*	cggcaaactcctcaagtgaatatt	cactgtcctgaggaatgaagcat
NM_012603	Myelocytomatosis oncogene	*Myc*	cgcctctgggaaactttgc	tcctggctcgcagattgtaa
NM_031144	Actin, beta	*Actb*	ccctggctcctagcaccat	agagccaccaatccacacaga

lents of malondialdehyde (MDA) amounts that were produced from 1,1,3,3,-tetramethoxypropane.

Preparation of microsomal fraction

The microsomal fractions were obtained according to the methods described by Yoshihara *et al.* (2001). Liver tissue samples (approximately 100 to 130 mg) obtained from Experiment 2 were homogenized in 700 μl of ice-cold buffer (containing 50 mM Tris-HCl; pH 7.4, 1.15% KCl, 0.2 mM ethylene diamine tetra-acetic acid, 0.1 mM DTT, 0.1 mM Protease Inhibitor Cocktail and 20% glycerol) using a pestle. The homogenate was centrifuged at 700 × g for 10 min at 4°C, and the supernatant was centrifuged at 10,000 × g for 20 min at 4°C. The 500 μl of supernatant was ultracentrifuged at 105,000 × g for 90 min. The microsomal pellet was resuspended in microsome buffer, and the protein content of the homogenate was measured using the BCA Protein Assay Kit (Pierce, IL, USA), with bovine serum albumin as a standard.

Microsomal reactive oxygen species production

NADPH-dependent microsomal ROS production was determined by measuring the oxidation of 2',7'-dichlorodihydrofluorescein diacetate (H_2DCFDA) to its fluorescent product 2',7'-dichlorofluorescein in liver microsomes according to the methods described by Schlezinger *et al.* (1999). The microsomes (final concentration 0.2 mg/ml) obtained from Experiment 1 were incubated in the dark at 37°C for 30 min in 50 mM Tris-HCl (pH 7.4) and 5 μM H_2DCFDA. In addition, 2.5 mM β-NADPH was

added. In some cases, 0.1 mM SKF-525A (Toronto Research Chemicals, ON, Canada), a well-known inhibitor of CYP, and 0.1 mM H_2O_2 as a positive control were added to the wells. The fluorescence was monitored every 5 minutes over 2 hr using a Synergy HT Multi-Detection Microplate Reader (BioTek) with excitation and emission wavelengths of 485 and 528 nm, respectively. The data were then normalized to the control values, with the control expressed as a value of 100%.

Plasma concentration of OPZ and BNF

To measure the plasma concentration of OPZ and BNF, the HPLC system (Waters chromatography division, Milford, MA, USA) was used in Experiment 1. Blood samples were collected from three rats each in the High OPZ, High BNF and OPZ+BNF groups. The blood sampling was performed one hour after administration of OPZ during the morning time. Chromatographic separation of OPZ or BNF was achieved using a Cadenza CD-C18 (3 μm, 4.6 mm I.D. × 150 mm, Imtakt) reverse phase analytical column. The mobile phase consisted of a mixture of 10 mmol/l phosphate buffer/acetonitrile (13:7, v/v adjusted pH to 7.3 with triethylamine) or a mixture of acetonitrile/25 mmol/l potassium dihydrogen phosphate (7:3, v/v). The mobile phase was pumped at an isocratic flow rate of 1.3 ml/min at 40°C or 1.5 ml/min at 40°C. The wavelength of UV detection was set at 302 and 285 nm for OPZ and internal standard solution (IS) (Lansoprazole: LPZ) assays, respectively or 274 nm for BNF and IS (hexyl 4-hydroxybenzoate) assays.

Plasma samples were collected at an hour after a final oral dose of OPZ. Plasma samples (400 μl) were transferred to a 15 ml glass tube, and 160 μl of diluent, 10 mmol/l disodium hydrogen phosphate for the OPZ assay, or a mixture of water/acetonitrile (1:1, v/v) for the BNF assay, was added. Then 40 μl of IS working solution (5 μg/ml) was spiked. A 2 ml aliquot of extraction solvent, tert-butyl methyl ether, was added and the sample was shaken for 10 min before being centrifuged for 3 min at 3,000 rpm. The organic layer (1.5 ml) was quantitatively transferred to a 6 ml glass tube and evaporated under a stream of nitrogen. The dried extract was then reconstituted with 200 μl of mobile phase, and a 20 μl aliquot was injected into chromatographic system.

For calibration samples, to 400 μl of blank rat plasma, 160 μl of working standard of OPZ or BNF was added, yielding final concentrations of 20-2,000 ng/ml of OPZ and BNF. To this mixture, 40 μl of IS working solution was added to yield IS concentration of 500 ng/ml.

Statistical analysis

All data were expressed as mean with standard deviation. Numerical data were evaluated using the following methods: A Bartlett's test for equal variance was used to determine if the variance was homogenous between the groups. If the variance was homogenous, numerical data were assessed using Dunnett's multiple comparison test. If a significant difference in variance was observed, the Steel test was used instead. In addition, to estimate the modifying effect of the combined administration, statistical analysis was performed using the method recommended by Futakuchi *et al.* (1996) and Hasegawa *et al.* (1991).

RESULTS

Experiment 1

Body and liver weights, food intake and BNF intake

In all treated groups, body weight significantly decreased when compared with the DEN alone group (Table 2). In the OPZ+BNF group, body weight significantly decreased when compared with other treated groups.

The absolute and relative liver weights significantly increased in the treated groups when compared with the DEN alone group. The relative liver weight in the OPZ+BNF group was approximately 1.8-fold higher than that in the DEN alone group, and was significantly higher than the High OPZ or High BNF groups (Table 2).

Food intake did not fluctuate with the treatment of OPZ or BNF, and average BNF intakes were 0.08 ± 0.01, 0.17 ± 0.01 and 0.09 ± 0.01 g/kg body weight/day in the Low BNF, High BNF and OPZ+BNF groups, respectively. The food efficiency in the DEN alone group, Low/High OPZ, Low/High BNF and OPZ+BNF groups was 0.17, 0.15, 0.15, 0.19, 0.16 and 0.11, respectively. A decreasing tendency of food efficiency was observed in the Low/High OPZ, High BNF and OPZ+BNF groups when compared to the DEN alone group.

Histopathology, GST-P-positive foci and PCNA-positive cells in the liver

Histopathologically, both OPZ and BNF induced diffuse hepatocellular hypertrophy with eosinophilic cytoplasm. Foci of cellular alterations of clear cells, eosinophilic cells and basophilic cells were observed in the treated groups. There was no inflammatory change in the OPZ, BNF and OPZ+BNF groups. Immunohistochemical analysis revealed that the number/area of GST-P-positive foci significantly increased in the treated groups (Table 2, Figs. 2a and b). In the OPZ+BNF group, the number of

Table 2. Final body and liver weights, food intake, BNF intake, number/area of GST-P-positive foci, PCNA-positive cells, ROS production and TBARS in the liver of male F344 rats given OPZ and/or BNF for 6 weeks after DEN treatment

Final body weight (g)	DEN alone	Low OPZ	High OPZ	Low BNF	High BNF	OPZ+BNF
No. of animals	11	12	12	9	12	11
Final body weight (g)	278.13 ± 9.65	258.86 ± 11.93$^{**,\#\#}$	255.59 ± 14.83$^{**,\#\#}$	267.62 ± 11.69$^{\#\#}$	260.68 ± 14.79$^{**,\#\#}$	233.01 ± 14.97**
Absolute liver weight (g)	8.25 ± 0.40	9.32 ± 0.67$^{**,\#\#}$	10.17 ± 0.84$^{**,\#\#}$	10.44 ± 0.91$^{**,\#}$	11.23 ± 0.89**	11.98 ± 1.40**
Relative liver weight (g/100 g body weight)	2.97 ± 0.10	3.60 ± 0.22$^{**,\#\#}$	3.97 ± 0.15$^{**,\#\#}$	3.90 ± 0.22$^{**,\#\#}$	4.30 ± 0.18$^{**,\#\#}$	5.14 ± 0.53**
Average food intake (g/kg body weight/day)	14.81 ± 1.12	14.48 ± 1.20	13.81 ± 1.10	14.11 ± 1.43	14.17 ± 1.58	13.50 ± 2.04
Average BNF intake (g/kg body weight/day)	-	-	-	0.08 ± 0.01	0.17 ± 0.01	0.09 ± 0.01
GST-P positive foci (≧ 0.2 mm)						
Numbers (number/cm^2)	3.18 ± 1.93	4.47 ± 1.65$^{\#\#}$	5.78 ± 2.18$^{*,\#\#}$	7.05 ± 1.45$^{**,\#\#}$	7.30 ± 2.45$^{**,\#\#}$	10.66 ± 2.76**
Areas (mm^2/cm^2)	0.20 ± 0.12	0.37 ± 0.27$^{\#\#}$	0.42 ± 0.20$^{*,\#\#}$	0.57 ± 0.20**	0.58 ± 0.31**	0.82 ± 0.34**
PCNA-positive cells (%)	0.29 ± 0.18	0.25 ± 0.19$^{\#}$	0.41 ± 0.18	0.36 ± 0.18	0.39 ± 0.22	0.64 ± 0.41*
No. of animals	5	5	5	5	5	5
ROS production (%)						
+NADPH	100.00 ± 16.72	75.19 ± 5.91**	71.77 ± 10.81**	91.12 ± 6.52	76.22 ± 15.32**	68.32 ± 7.55**
+NADPH+SKF525A	48.55 ± 7.32	42.74 ± 5.43	45.23 ± 8.35	43.77 ± 5.24	47.25 ± 6.76	43.17 ± 4.94
-NADPH	21.36 ± 2.54	21.36 ± 1.10	21.24 ± 1.08	21.91 ± 2.05	17.00 ± 9.59	20.96 ± 3.14
No. of animals	6	6	6	6	6	6
TBARS (nmol MDA/mg protein)	0.97 ± 0.08	0.99 ± 0.06	1.00 ± 0.05	1.00 ± 0.04	1.01 ± 0.12	0.93 ± 0.07

DEN, *N*-diethylnitrosamine; Low OPZ, 138 mg/kg omeprazole; High OPZ, 276 mg/kg omeprazole; Low BNF, 0.125% β-naphthoflavone; High BNF, 0.25% β-naphthoflavone; and OPZ+BNF, 138 mg/kg omeprazole + 0.125% β-naphthoflavone. The data represent mean ± S.D.

*, ** significantly different from the DEN alone group at $P < 0.05$ or 0.01.

#, ## significantly different from the OPZ +BNF group at $P < 0.05$ or 0.01.



Fig. 2. Number and area of GST-P-positive foci in rats given OPZ and/or BNF after DEN initiation. Each bar shows the number (A) and area (B) of GST-P-positive foci in the liver of rats given DEN alone (DEN alone), 138 mg/kg OPZ (Low OPZ), 276 mg/kg OPZ (High OPZ), 0.125% BNF (Low BNF), 0.25% BNF (High BNF) or 138 mg/kg OPZ+0.125% BNF (OPZ+BNF). *, ** significantly different from the DEN alone group at $P < 0.05$ or $P < 0.01$, respectively. ## significantly different from the OPZ+BNF group at $P < 0.01$.

GST-P-positive foci significantly increased when compared with the OPZ treated and BNF treated groups, and the area of GST-P-positive foci significantly increased when compared with the OPZ treated groups. Meanwhile, the number of PCNA-positive cells significantly increased in the OPZ+BNF groups when compared with the DEN alone group (Table 2).

DNA microarray and real-time RT-PCR analyses

Hepatic gene expression changes in rats from the DEN alone, Low OPZ, Low BNF and OPZ+BNF groups were screened using an oligonucleotide microarray. In the microarray, 4,439 genes showed more than a 2-fold increase or more than a half-fold decrease in their expression in one rat each from the OPZ, BNF and OPZ+BNF groups when compared with a rat of the DEN alone group (supplementary data). We focused on the AhR battery and oxidative stress response-related genes. Real-time RT-PCR analysis on the genes listed in Table 1 was performed using liver samples (6 rats/group) (Table 3).

In real-time RT-PCR analysis, the expression of *Cyp1a1*, *Cyp1a2*, *Cyp1b1*, *Ugt1a6* and *Nqo1*, which are phase I metabolic enzymes and are regulated by AhR, significantly increased in the treated groups when compared with the DEN alone group. Of these genes, the expression of *Cyp1a2, Cyp1b1, Ugt1a6* and *Nqo1* significantly increased in the OPZ+BNF group when compared with the Low OPZ or Low BNF groups (Table 3). The expression of *Aldh1a1* and *Cyp2b2* significantly increased in the OPZ treated groups, but showed a decreasing tendency in the OPZ+BNF group when compared with the OPZ treated group. On the other hand, *Aldh3a1* significantly increased in the BNF treated groups when compared with the DEN alone group, and significantly increased in the OPZ+BNF group when compared with the Low OPZ or Low BNF groups. In addition, the expression of *Ahrr* significantly increased in the BNF and OPZ+BNF groups, and significantly increased in the OPZ+BNF group when compared with the OPZ and BNF treated groups.

In phase II metabolic enzymes, the expression of *Akr7a3*, *Gpx2*, *Yc2* and *Me1* significantly increased in the treated groups when compared with the DEN alone group. Of these genes, *Gpx2* and *Yc2* significantly increased in the OPZ+BNF group when compared with the Low OPZ or Low BNF groups. The expression of *Akr7a3* and *Me1* in the OPZ+BNF group showed an increasing tendency when compared with the Low OPZ or Low BNF group (Table 3).

In inflammation-related genes, the expression of *Cox2*, *Serpine1*, *Mmp12* and *Fgf21* significantly increased in the BNF treated groups when compared with the DEN alone groups, and significantly increased or showed an increasing tendency in the OPZ+BNF group when compared with the other treated groups. The expression of *Il-6* showed an increasing tendency in the OPZ+BNF group when compared with the DEN alone group. The expression of *Nfkb1* and *Nfkbia* did not fluctuate in the treated groups but the expression of *Tnf* significantly increased in the High BNF group (Table 3).

In cell cycle-related genes, the expression of *Chek1*

Table 3. Real-time RT-PCR analysis of the liver tissues from male F344 rats given OPZ and/or BNF for 6 weeks after DEN treatment

Group	DEN alone	Low OPZ	High OPZ	Low BNF	High BNF	OPZ+BNF
AhR-regulated genes						
Cyp1a1	1.19 ± 0.67	158.19 ± 197.79$^{**,\#\#}$	138.19 ± 120.20$^{**,\#\#}$	2842.87 ± 824.82**	3357.84 ± 831.00**	3138.85 ± 579.83**
Cyp1a2	1.01 ± 0.18	6.50 ± 1.95$^{**,\#\#}$	6.93 ± 2.83$^{**,\#\#}$	27.79 ± 4.53$^{**,\#\#}$	42.91 ± 6.37**	52.03 ± 11.37**
Cyp1b1	1.06 ± 0.38	4.04 ± 2.15$^{**,\#\#}$	3.28 ± 1.15$^{*,\#\#}$	188.10 ± 50.95$^{**,\#\#}$	706.52 ± 297.60**	1117.09 ± 263.51**
Cyp2b2	1.05 ± 0.34	5.17 ± 1.26$^{**,\#\#}$	6.66 ± 2.57$^{**,\#\#}$	0.66 ± 0.13	0.53 ± 0.17*	0.92 ± 0.40
Aldh1a1	1.08 ± 0.52	3.50 ± 0.92**	3.67 ± 1.45*	1.25 ± 0.12$^{\#\#}$	1.98 ± 0.39*	2.30 ± 0.64*
Aldh3a1	1.23 ± 0.80	1.80 ± 1.02$^{\#\#}$	1.32 ± 0.54$^{\#\#}$	2.56 ± 0.89$^{\#\#}$	90.70 ± 66.77$^{**,\#\#}$	860.74 ± 361.47**
Nqo1	1.03 ± 0.29	2.54 ± 0.88$^{**,\#\#}$	2.81 ± 0.75$^{**,\#\#}$	5.40 ± 0.58$^{**,\#\#}$	10.10 ± 2.85$^{**,\#}$	16.86 ± 3.37**
Ugt1a6	1.03 ± 0.25	1.86 ± 0.35$^{**,\#}$	1.71 ± 0.50$^{*,\#\#}$	1.62 ± 0.18$^{*,\#\#}$	2.45 ± 0.54$^{**,\#}$	3.85 ± 0.86**
Ahrr	2.62 ± 4.31	7.52 ± 3.70$^{\#\#}$	8.62 ± 4.86$^{\#\#}$	55.52 ± 20.05$^{*,\#}$	138.07 ± 52.11*	196.60 ± 71.27*
Nrf2-regulated genes						
Akr7a3	1.01 ± 0.17	3.28 ± 1.03**	4.78 ± 2.18**	1.88 ± 0.71$^{**,\#\#}$	3.25 ± 1.20**	5.75 ± 3.77**
Gpx2	1.04 ± 0.29	4.63 ± 1.5$^{**,\#}$	6.18 ± 1.51**	2.90 ± 0.80$^{**,\#}$	6.89 ± 2.74**	9.18 ± 3.10**
Yc2	1.00 ± 0.10	1.73 ± 0.36$^{**,\#}$	1.73 ± 0.27**	1.26 ± 0.18$^{*,\#\#}$	1.60 ± 0.25$^{**,\#}$	2.42 ± 0.60**
Me1	1.08 ± 0.39	2.35 ± 0.77**	2.57 ± 0.62**	1.94 ± 0.51$^{*,\#}$	1.93 ± 0.88$^{*,\#}$	4.14 ± 2.20**
Inflammation						
Cox2	1.07 ± 0.36	1.52 ± 0.35	1.30 ± 0.22	2.89 ± 0.99**	3.31 ± 1.31**	3.61 ± 1.87*
Serpine1	1.02 ± 0.24	0.95 ± 0.24$^{\#}$	0.99 ± 0.46$^{\#}$	1.59 ± 0.37$^{*,\#}$	2.23 ± 1.18$^{*,\#}$	3.16 ± 0.42**
Mmp12	1.01 ± 0.14	1.01 ± 0.53$^{\#}$	0.90 ± 0.27$^{\#}$	1.26 ± 0.18	2.14 ± 0.65*	2.28 ± 1.24**
Il-6	1.19 ± 0.88	2.12 ± 0.64	1.28 ± 0.80	1.37 ± 0.62	1.37 ± 0.41	2.72 ± 1.98
Fgf21	1.08 ± 0.54	0.94 ± 0.46$^{\#}$	0.94 ± 0.45$^{\#}$	1.68 ± 0.52	1.97 ± 0.80	3.35 ± 2.29*
Nfkb1	1.01 ± 0.16	1.04 ± 0.14	0.94 ± 0.17	0.96 ± 0.07	1.12 ± 0.16	1.00 ± 0.16
Nfkbia	1.1 ± 0.47	1.05 ± 0.39	0.9 ± 0.32	0.6 ± 0.27	0.65 ± 0.17	0.98 ± 0.56
Tnf	1.02 ± 0.22	1 ± 0.2	0.91 ± 0.15	1.23 ± 0.32	1.59 ± 0.26*	1.28 ± 0.46
Cell cycle related genes						
Chek1	1.01 ± 0.17	1.29 ± 0.31	1.41 ± 0.28**	1.14 ± 0.17$^{\#\#}$	1.27 ± 0.34$^{\#}$	1.69 ± 0.34**
Wee1	1.01 ± 0.15	1.36 ± 0.33	1.43 ± 0.34	1.43 ± 0.19	1.60 ± 0.57*	1.86 ± 0.28**
MAP kinase pathway family related genes						
Myc	1.03 ± 0.26	2.59 ± 1.15*	3.00 ± 1.18*	1.10 ± 0.43$^{\#\#}$	1.50 ± 0.52$^{\#}$	3.15 ± 1.62**

DEN, *N*-diethylnitrosamine; Low OPZ, 138 mg/kg omeprazole; High OPZ, 276 mg/kg omeprazole; Low BNF, 0.125% β-naphthoflavone; High BNF, 0.25% β-naphthoflavone; and OPZ+BNF, 138 mg/kg omeprazole + 0.125% β-naphthoflavone. The data represent mean ± S.D.

*, ** significantly different from the DEN alone group at $P < 0.05$ or 0.01.

$^{\#}$, $^{\#\#}$ significantly different from the OPZ +BNF group at $P < 0.05$ or 0.01.

significantly increased in the High OPZ and OPZ+BNF groups when compared with the DEN alone group, and the expression of *Wee1* significantly increased in the High BNF and OPZ+BNF groups (Table 3).

In other genes, the expression of *Myc* significantly increased in the OPZ and OPZ+BNF groups when compared with the DEN alone group (Table 3).

Microsomal ROS production

To estimate the cellular sources of ROS, NADPH-dependent ROS production was measured in liver microsomes. The oxidized indicator was not detected in the absence of NADPH. With the addition of NADPH into the microsomal system, ROS production was dramatically enhanced, but ROS production significantly decreased in the OPZ treated, high BNF and OPZ+BNF groups when compared with the DEN alone group (Table 2). SKF-525A, a well-known inhibitor of CYP, inhibited NADPH-dependent ROS production.

Oxidative stress on cellular membrane

To evaluate whether oxidative damages to cellular components occurred, TBARS formation was determined in the liver. There was no remarkable change in TBARS content between the groups (Table 2).

Immunohistochemistry of COX-2 in the liver

COX-2-positive cells, which are recognized as Kupffer cells, were observed in the sinusoid of the livers (Fig. 3). COX-2-positive cells were mainly observed in the periportal areas of the liver in the DEN alone group, but were scattered throughout the liver in the BNF and OPZ+BNF groups. In addition, COX-2-positive Kupffer cells were observed in the periphery of some foci of the OPZ+BNF group (Fig 4). The number of COX-2-positive cells in the OPZ+BNF group significantly increased when compared with the DEN alone group (Fig. 3).

Plasma concentration of OPZ and BNF

We estimated the plasma concentration of OPZ and BNF at necropsy (Table 4). In the High BNF and OPZ+BNF groups, the plasma concentration of BNF could not be detected (less than the limit of quantitation: 20 ng/ml). However, the concentration of OPZ was 6,053 ± 2,409 ng/ml in the High OPZ group and 310 ± 241 ng/ml in the OPZ+BNF group.

Experiment 2

Body and liver weights

In all groups, no significant changes in body weights were observed in the treated groups when compared with the MeIQx alone group (Table 5). Absolute liver weights significantly increased in the High BNF group, and relative liver weights significantly increased in the High BNF and OPZ+BNF groups when compared with the DEN alone group (Table 5). The relative liver weights in the OPZ+BNF group significantly increased when compared with the Low OPZ group.

Histopathological examinations and GST-P-positive foci in the liver

Immunohistochemical analysis revealed that the number and area of GST-P-positive foci significantly increased only in the Low BNF group, but not in the High BNF and OPZ+BNF groups (Table 5). Because of there being no dose-relationship in the induction of GST-P-positive foci in BNF treated groups, it was concluded that BNF did not have liver initiation activity. No apparent difference in the localization of GST-P-positive foci with respect to zones 1-3 was observed among the groups. There was no change in the number of PCNA-positive cells among the groups (Table 5).

DISCUSSION

It has previously been demonstrated that the simultaneous administration of several chemicals induced additive or synergistic effects on the carcinogenicity in rats (Hasegawa *et al.*, 1989). The combined administration of hepatocarcinogens such as 2-AAF, benzo[a]pyrene (B[a]

Table 4. Plasma concentration of male F344 rats given OPZ and/or BNF for 6 weeks after DEN treatment

group	plasma OPZ concentration	plasma BNF concentration
High OPZ	3470	BLQ
	6450	BLQ
	8240	BLQ
High BNF	BLQ	BLQ
	BLQ	BLQ
	BLQ	BLQ
OPZ+BNF	203	BLQ
	586	BLQ
	141	BLQ

High OPZ, 276 mg/kg omeprazole; High BNF, 0.25% β-naphthoflavone; and OPZ+BNF, 138 mg/kg omeprazole + 0.125% β-naphthoflavone.
BLQ: Below limit of quantification (less than 20 ng/ml)



Fig. 3. Immunohistochemical photographs of COX-2 and the number of COX-2-positive cells in the liver of rats given OPZ and/or BNF after DEN initiation. Each photograph shows COX-2-positive cells in the liver of the DEN alone group (a), Low OPZ group (b), Low BNF group (c), and OPZ+ BNF group (d). Original magnification: × 100 (bar: 100 μm). The bar shows mean + S.D. of the number of COX-2 positive-cells in each group. *significantly different from the DEN alone group at $P < 0.05$.



Fig. 4. Immunohistochemical photographs of COX-2 (a) and GST-P (b) in the liver of a rat given OPZ and BNF after DEN initiation. COX-2-positive cells are prominent around the altered focus (a), and the focus gives close agreement with GST-P (b). Original magnification: × 100 (bar: 100 μm).

P) and N-ethyl-N-hydroxyethylnitrosamine at low doses resulted in synergistic effects in the rat liver (Hasegawa *et al.*, 1989). In addition, in the two-stage forestomach carcinogenesis model, the combined administration of promoters/carcinogens exerted a strong enhancing influence on the forestomach carcinogenesis in rats, although the low doses of them did not have a significant promoting activity (Hirose *et al.*, 1991). Synergism occurs when the effect of two or more substances acting together exceeds the sum of their effects when acting separately (Reif *et al.*, 1984). Hasegawa *et al.* (1991) examined potential synergism between five HCAs (3-amino-1-methyl-

Table 5. Final body and liver weights, number/area of GST-P-positive foci, distribution of GST-P-positive foci and number of PCNA-positive cells in the liver of male F344 rats given OPZ and/or BNF for 9 days before MeIQx treatment

Group	MeIQx alone	Low OPZ	High OPZ	Low BNF	High BNF	OPZ+BNF
No. of animals	12	10	12	11	11	11
Final body weight (g)	257.8 ± 9.8	259.2 ± 9.0	254.9 ± 10.6	261.6 ± 13.5	259.8 ± 6.1	256.6 ± 12.9
Absolute liver weight (g)	9.14 ± 0.53	9.37 ± 0.52	9.26 ± 0.62	9.73 ± 0.84	9.87 ± 0.27**	9.59 ± 0.69
Relative liver weight (g/100g body weight)	3.58 ± 0.13	3.59 ± 0.10#	3.61 ± 0.12	3.68 ± 0.19	3.79 ± 0.13**	3.73 ± 0.11*
GST-P-positive foci (≧ 0.2 mm)						
Number (number/cm²)	0.38 ± 0.60	0.18 ± 0.25	0.83 ± 1.24	1.41 ± 1.29*	1.44 ± 1.47	0.78 ± 1.21
Area (mm²/cm²)	0.02 ± 0.03	0.01 ± 0.02	0.06 ± 0.09	0.10 ± 0.09*	0.14 ± 0.22	0.05 ± 0.11
% of GST-P-positive foci for each zone						
Zone 1	0	20.8 ± 25.0	12.5 ± 35.4	13.0 ± 14.5	17.8 ± 21.1	33.4 ± 43.8
Zone 2	68.0 ± 29.5	37.5 ± 47.9	76.0 ± 37.1	51.6 ± 19.3	57.5 ± 29.0	56.7 ± 42.1
Zone 3	32.0 ± 29.5	41.7 ± 44.1	11.5 ± 21.3	39.1 ± 20.6	24.7 ± 20.7	9.9 ± 17.7
PCNA-positive hepatocyte (%)	0.51 ± 0.54	0.40 ± 0.25	0.40 ± 0.48	0.39 ± 0.28	0.50 ± 0.97	0.43 ± 0.36

MeIQx: 2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline, Low OPZ: 138 mg/kg omeprazole, High OPZ: 276 mg/kg omeprazole, Low BNF: 0.03% β-naphthoflavone, High BNF: 0.06% β-naphthoflavone, OPZ+BNF: 138 mg/kg omeprazole+0.03% β-naphthoflavone.
The data represent mean ± S.D.
*, ** significantly different from the MeIQx alone group at $P < 0.05$, 0.01.

5*H*-pyrido[4,3-*b*]indole, 2-amino-6-methyldipyrido[1,2-*a*:3',2'-*d*]-imidazole, 2-amino-3-methyl-9*H*-pyrido[2,3-*b*] indole, 2-amino-9*H*-pyrido[2,3-*b*]indole and 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine). In their report, a heteroadditive model was used, and net values were obtained by subtracting the control value (DEN-alone group). In the heteroadditive model, they compared the net value for the combined treatment and the sum of the net value of individual treatment at 1/5 dose, and the net value for the combined treatment was greater than the sum of net values in 1/5 dose. They concluded that the combination effects were synergistic. However, dose-response curves were not considered in this model. Reif (1984) pointed out the importance of the dose response curve in the analysis of the combined effects, and described that in ordinary heteroadditive methods the combined effect could be evaluated whether it was synergistic or not. In this heteroadditive model, the consideration of the dose response curves was lacking. On the other hand, Hasegawa *et al.* (1994, 1995) examined the combination effect of ten HCAs at low doses using two statistical models, a heteroadditive model and an isoadditive model. In the heteroadditive model, significant greater effects were found in the combination group. On the other hand, in the isoadditive model, Hasegawa *et al.* (1994, 1995) compared the average value of individual treatments of 1/1 dose and the value of ten heterocyclic amines and the combination treatment at 1/10 dose. As a result, since a significant increase was not shown in the combination group, they concluded that this combination effect was not synergistic in the isoadditive model. Futakuchi *et al.* (1996) examined potential synergism between four N-nitroso compounds (nitrosomorpholine, nitrosodimethylamine, nitrosodiethanolamine, and nitroso-oxazolidine) in rat liver carcinogenesis in a medium-term bioassay where male F344 rats were initially given DEN, and 2 weeks later received test chemicals for a period of 6 weeks at a full or 1/4 dose of that proven to be carcinogenic, individually or in combination. In their report, the effect value of individual chemicals was obtained by subtracting the control value (DEN-alone group). In the heteroadditive model, they compared the sum of the effect values of each individual treatment at 1/4 dose and the value for rats treated with four chemicals in combination at the 1/4 dose level, and no significant increase was observed between them. However, in the isoadditive model, the value in combination at the 1/4 dose level treatment was almost the same as the average of four individual treatments at full dose and, the value in combination at 1/16 dose level treatment were not significantly higher than the average value of four individual treatment at 1/4 dose. They concluded that the combined effects were not synergistic but isoadditive. In the present study (Experiment 1), we demonstrated that the combined administration of low doses of OPZ and BNF induced higher numbers of GST-P-positive foci when compared with the high doses of OPZ or BNF, and induced higher areas of GST-P-positive foci when compared with high dose of OPZ. In the heteroadditive model, the effect value of the combination at a low dose (area, 0.67 mm^2/cm^2; number, 8.08 $number/cm^2$; average of value of OPZ+BNF minus value of DEN-alone) was not significantly higher than the sum of the effect value of both OPZ and BNF at low dose (area, 0.55 mm^2/cm^2; number, 5.34 $number/cm^2$). However, in the isoadditive model, the value of the combined administration of low doses of OPZ and BNF (area, 0.82 ± 0.34 mm^2/cm^2; number, 10.66 ± 2.76 $number/cm^2$) was significantly higher ($P < 0.05$, *t* test) than the average value of each individual treatment at a high dose of OPZ and BNF (area, 0.50 ± 0.27 mm^2/cm^2; number, 6.53 ± 2.40 $number/cm^2$; average of value of High OPZ and value of High BNF). Therefore, it can be concluded that the combined liver tumor promotion effect of OPZ and BNF is synergistic in the isoadditive model.

In Experiment 1, phase I metabolic enzymes such as *Cyp1a1*, *Cyp1a2*, *Cyp1b1*, *Nqo1* and *Ugt1a6*, which are called as AhR gene battery and induced by AhR, significantly increased or showed an increasing tendency in the OPZ+BNF group when compared with the Low OPZ or Low BNF group. Aryl-hydrocarbon receptor repressor (AHRR) is activated by the AhR ligand in heterodimer with aryl hydrocarbon receptor nuclear translocator (ARNT), and expressed AHRR inhibits the AhR function (Brauze *et al.*, 2006). AhR and AHRR constitute a negative regulatory feedback loop of xenobiotic signal transductions (Brauze *et al.*, 2006). In the OPZ+BNF group, the expression of *Ahrr* significantly increased or showed an increasing tendency when compared with the treated groups, suggesting the enhanced transduction of AhR. In addition, phase II metabolic enzymes such as *Akr7a3*, *Gpx2*, *Yc2* and *Me1* significantly increased in the treated groups, and significantly increased or showed an increasing tendency in the OPZ+BNF group when compared with the other treated groups. Nrf2 is activated by oxidative stress and induces detoxification enzymes and antioxidants (Köhle and Bock, 2007). It is generally accepted that the microsomal electron system, including CYPs and NADPH-CYP reductase generates ROS through the metabolism, with the subsequent formation of an oxygenated substrate and water (Poulos and Raag, 1992). Although electron transfer is normally a well-coupled process, superoxide and H_2O_2 may be released in

the presence of CYP1A inducers that are poorly metabolized (Puntarulo and Cederbaum, 1998; Nishikawa *et al.*, 2002). Therefore, upregulation of these genes suggests that the increment of ROS production contributes to the enhancement of the liver tumor promoting effect in the OPZ+BNF group. However, microsomal ROS production significantly decreased in the OPZ+BNF group, and no fluctuations of TBARS were observed in the treated groups. Oxidative stress usually occurs when ROS production in cells or tissues exceeds the antioxidant potential (Klaunig *et al.*, 1998). Therefore, it is possible that the antioxidant regulated by Nrf2 probably exceeds the ROS production and removes the ROS generated in the OPZ+BNF group.

It has been demonstrated in our previous studies that COX-2 is related to the liver tumor promoting effect of BNF (Shimada *et al.*, 2010; Kuwata *et al.*, 2011). COX-2 may be involved in the early stage of hepatocarcinogenesis, and the increased expression of COX-2 in non-cancerous liver tissues has been significantly associated with shorter disease-free survival in patients with hepatocellular carcinomas (Cervello and Montalto, 2006). In tumors in human, overexpression of COX-2 leads to an increase in prostaglandin (PG) levels which affects many mechanisms involved in carcinogenesis, such as angiogenesis, inhibition of apoptosis, and stimulation of cell growth, as well as invasiveness and the metastatic potential of tumor cells (Cervello and Montalto, 2006). Several reports suggest that OPZ might have an anti-inflammation effect (Kedika *et al.*, 2009; Shivanna *et al.*, 2011). Indeed, OPZ inhibited ROS production and protected against oxidative stress by inducing *heme-oxygenase-1* (Kedika *et al.*, 2009; Shivanna *et al.*, 2011). However, the ligands of AhR, including TCDD and B[a]P, induced *Cox-2* expression (Degner *et al.*, 2007 and 2009). TCDD and B[a]P induced transcription activity of COX-2 in breast cancer MCF-7 cells (Degner *et al.*, 2007). Furthermore, the TCDD-association of AhR to xenobiotics responsive elements in the *Cox-2/Cyp1a* promoter was inhibited by AhR antagonists such as 3,3'-diindolulmetahane and resveratrol (Denger *et al.*, 2007). On the other hand, TCDD increases the intracellular concentration of free Ca^{2+} and subsequently activates cytosolic phospholipase A2 and additional inflammatory marker, *Cox-2*, expression in U937 macrophages (Sciullo *et al.*, 2008). In the present study, the expression of *Nfkb1*, *Nfkbia* and *Tnf*, which are regulated by Nfkb, did not fluctuate in the OPZ+BNF group. However, the expression of *Cox-2* significantly increased in the OPZ+BNF group when compared with the DEN alone group, and COX-2 protein also significantly increased in this group. Therefore, these data indicate that the activation of AhR contributes to the enhancement of COX-2, and it can be suggested that the combined administration of OPZ and BNF, which are the ligands of AhR, may induce COX-2 via AhR and enhance the liver tumor promoting effect in rats. On the contrary, the induction of *Cyp1a* by AhR was induced in hepatocytes, but it is not clear whether the induction of *Cox-2* in Kupffer cells occurred in the same mechanism. Recently, it has been reported that tumor microenvironment is related to the hepatocarcinogenesis (Yang *et al.*, 2011). Kupffer cells induce programmed death ligand-1, which impairs cytotoxic $CD8^+$ T cell function in human hepatocellular carcinomas (Yang *et al.*, 2011). Kupffer cells also produce IL-6 and osteopontin that play a pivotal role in various cell signaling pathways promoting inflammation, tumor progression and metastasis. Therefore, Kupffer cells expressing COX-2 might have been related to the liver tumor promoting effect.

CHEK1 is phosphorylated in response to DNA damage and is essential for cell-cycle arrest in response to DNA damage or DNA replication blockage (Niida and Nakanishi, 2006). WEE1 is a tyrosine kinase that controls the cell cycle in response to DNA damage (Raleigh and O'Connell, 2000). When DNA damage is induced in the G2 phase, Wee1 phosphorylates cyclin-dependent kinase 2 (cdc2) and inactivates cdc2, and prevents the entry into mitosis phase (Raleigh and O'Connell, 2000). OPZ showed a weak genotoxicity in primary rat hepatocytes (Martelli *et al.*, 1998). In the present study, the expression of *Chek1* and *Wee1* significantly increased in the OPZ+BNF group when compared with the DEN alone group. In addition, the expression of *Myc* significantly increased in the OPZ treated and OPZ+BNF groups. Myc has a neoplastic potential and plays an important role in regulating cell proliferation (Dang, 1999). Impaired expression of Myc is related to the development of many malignant tumors in humans and animals (Hoffman and Liebermann, 1998). OPZ has a liver tumor promoting effect in rats, but the mechanism is not clear. Taking into account these points, it can be considered that the involvement of DNA damage and increased expression of *Myc* are related to the enhancement of liver tumor promoting effects of OPZ and BNF, although further study is needed.

The plasma concentration of BNF could not be detected. However, the concentration of OPZ was 6,053 ± 2,409 ng/ml in the High OPZ group and 310 ± 241 ng/ml in the OPZ+BNF group. OPZ is metabolized via hepatic CYP1A1/2, 2D1, 3A1/2 in rats (Lee *et al.*, 2009). In the OPZ+BNF group, the expression of *Cyp1a1* and *1a2* increased when compared with the Low OPZ and Low

BNF groups. This finding suggests that the induction of liver drug-metabolizing enzyme by BNF may affect the metabolism of OPZ in the OPZ+BNF group. It has previously been shown that the plasma concentration of BNF reaches a maximal level at 80-120 min and then starts declining toward a lower plateau value in SD rats given a continuous intravenous infusion of 1.5 or 6 mg/kg/hr BNF for 6 hr (Chen *et al.*, 2010). BNF is known as a substrate of CYP1A enzymes and the BNF clearance increases with time after continuous intravenous infusion to rats (Chen *et al.*, 2010). Such a time-dependent increase in clearance supports the present finding of plasma BNF concentrations not being detected in BNF treated rats. In addition, the exponential increase of plasma concentration of OPZ was not observed with the combined administration of OPZ and BNF. On the other hand, the expression of *Cyp1a1* in the 0.5% BNF group was 299-fold higher than that of the DEN alone group when they were fasted for 12 hours (Shimamoto *et al.*, 2011b), while the expression of *Cyp1a1* without fasting in the 0.25% BNF group of our study was 3357-fold higher than that of the DEN alone group. Therefore, since the expression of genes such as *Cyp1a1* and *Cyp1a2* significantly increased in the OPZ+BNF group, it is likely that some unknown metabolic effect due to the combined administration intensifies the liver tumor promoting effect.

MeIQx is activated by CYP1A2, and the metabolites produced are highly reactive and bind covalently to DNA (Yamazoe *et al.*, 1988). Previous reports have shown that CYP1A2 inducers such as fenbendazole and caffeine did not enhance the MeIQx-induced hepatocarcinogenesis in rats (Suzuki *et al.*, 2002; Kuribayashi *et al.*, 2006). It has also been reported that BNF did not enhance the MeIQx-induced hepatocarcinogenesis in rats (Suzuki *et al.*, 2010). In that study, CYP1A expression was mainly observed in the area adjacent to the central veins (zone 3) of the liver, where GST-P-positive foci were preferentially located, in MeIQx-treated rats; while BNF treatment induced CYP1A in the area adjacent to Glisson's sheath (zone 1). Taken into account the distribution differences of the CYP1A induction between MeIQx and BNF, Suzuki *et al.* (2010) speculated that the difference of CYP1A expression may be related to MeIQx-induced hepatocarcinogenesis. In the present study, no apparent difference in distribution of GST-P-positive foci was observed among the groups. Although CYP1A2 activates MeIQx, CYP1A1 is thought to be related to the detoxification of MeIQx (Suzuki *et al.*, 2002). Indole-3-carbinol, which is a chemopreventive compound, preferentially induces CYP1A1 rather than CYP1A2 and inhibits the HCA-induced carcinogenicity by shifting the metabolism of HCAs (Hirata *et al.*, 2008). In our previous studies, OPZ and BNF also induced expression of both *Cyp1a1* and *Cyp1a2* in rats, and preferentially induced *Cyp1a1* rather than *Cyp1a2* (Hayashi *et al.*, 2012a, 2012b). In addition, the expression of NATs in the liver did not fluctuate with the administration of BNF (Suzuki *et al.*, 2002). Because MeIQx is activated by NAT, no induction of NAT may result in the unchanged initiation activities. In the present study, no enhancement of MeIQx-induced hepatocarcinogenesis was observed in the OPZ+BNF group, although the number and area of GST-P-positive foci increased in the Low BNF group but not in the High BNF group. Therefore, enhanced liver initiation activity may not be induced by the treatment of two different chemicals that have similar capabilities to induce both CYP1A1 and CYP1A2.

In conclusion, the co-administration of OPZ and BNF resulted in an enhanced liver tumor promoting effect but not liver initiation activity in rats. The outcome of the present study suggests the possibility that the combined liver tumor promotion effect of two different compounds that have similar capabilities to induce CYP1A is synergistic. Currently, regulatory agencies in individual countries set the acceptable daily intake for chemicals in food. However, particular attention should be paid to the combined exposure of plural chemicals in food that are recognized as CYP inducers. In order to eliminate the enhanced adverse effects from simultaneous exposure to plural chemicals that have the capability of inducing CYPs, we must reconsider the risk evaluation of these chemicals. As our data are limited to the combined administration of OPZ and BNF only, further examination using other CYP inducers is vital.

ACKNOWLEDGMENT

This study was partly supported by a grant in-aid for research on the safety of veterinary drugs in food of animal origin from the Ministry of Health, Labour and Welfare of Japan (H22-Shokuhin-Ippan-007).

Supplementary data

Supplementary data associated with this article can be found in the online version.

REFERENCES

Brauze, D., Widerak, M., Cwykiel, J., Szyfter, K. and Baer-Dubowska, W. (2006): The effect of aryl hydrocarbon receptor ligands on the expression of AhR, AhRR, ARNT, Hif1alpha, CYP1A1 and NQO1 genes in rat liver. Toxicol. Lett., **167**, 212-220.

Cervello, M. and Montalto, G. (2006): Cyclooxygenases in hepatocellular carcinoma. World J. Gastroenterol., **12**, 5113-5121.

Chen, E.P., Chen, L., Ji, Y., Tai, G., Wen, Y.H. and Ellens, H. (2010): A mechanism-based mathematical model of aryl hydrocarbon receptor-mediated CYP1A induction in rats using beta-naphthoflavone as a tool compound. Drug Metab. Dispos., **38**, 2278-2285.

Dang, C.V. (1999): c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol., **19**, 1-11.

Degner, S.C., Kemp, M.Q., Hockings, J.K. and Romagnolo, D.F. (2007): Cyclooxygenase-2 promoter activation by the aromatic hydrocarbon receptor in breast cancer mcf-7 cells: repressive effects of conjugated linoleic acid. Nutr. Cancer., **59**, 248-257.

Degner, S.C., Papoutsis, A.J., Selmin, O. and Romagnolo, D.F. (2009): Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells. J. Nutr., **139**, 26-32.

Dewa, Y., Nishimura, J., Muguruma, M., Jin, M., Saegusa, Y., Okamura, T., Tasaki, M., Umemura, T. and Mitsumori, K. (2008): Beta-Naphthoflavone enhances oxidative stress responses and the induction of preneoplastic lesions in a diethylnitrosamine-initiated hepatocarcinogenesis model in partially hepatectomized rats. Toxicology, **244**, 179-189.

Dewa, Y., Nishimura, J., Muguruma, M., Jin, M., Kawai, M., Saegusa, Y., Okamura, T., Umemura, T. and Mitsumori, K. (2009): Involvement of oxidative stress in hepatocellular tumor-promoting activity of oxfendazole in rats. Arch. Toxicol., **83**, 503-511.

Futakuchi, M., Lijinsky, W., Hasegawa, R., Hirose, M., Ito, N. and Shirai, T. (1996): Effects of low dose mixtures of four N-nitroso compounds on hepatic foci development in the rat. Cancer Lett., **106**, 263-269.

Hayashi, H., Shimamoto, K., Taniai, E., Ishii, Y., Morita, R., Suzuki, K., Shibutani, M. and Mitsumori, K. (2012a): Liver tumor promoting effect of omeprazole in rats and its possible mechanism of action. J. Toxicol. Sci., **37**, 491-501.

Hayashi, H., Taniai, E., Morita, R., Yafune, A., Suzuki, K., Shibutani, M. and Mitsumori, K. (2012b): Threshold dose of liver tumor promoting effect of β-naphthoflavone in rats. J. Toxicol. Sci., **37**, 517-526.

Hasegawa, R., Miyata, E., Futakuchi, M., Hagiwara, A., Nagao, M., Sugimura, T. and Ito, N. (1994): Synergistic enhancement of hepatic foci development by combined treatment of rats with 10 heterocyclic amines at low doses. Carcinogenesis, **15**, 1037-1041.

Hasegawa, R., Mutai, M., Imaida, K., Tsuda, H., Yamaguchi, S. and Ito, N. (1989) Synergistic effects of low-dose hepatocarcinogens in induction of glutathione S-transferase P-positive foci in the rat liver. Jpn. J. Cancer Res., **80**, 945-951.

Hasegawa, R., Shirai, T. and Ito, N. (1995): Enhancement of liver carcinogenesis by combined treatment of rats with heterocyclic amines. Environ. Mutat. Res. Commun., **17**, 83-91.

Hasegawa, R., Shirai, T., Hakoi, K., Takaba, K., Iwasaki, S., Hoshiya, T., Ito, N., Nagao, M. and Sugimura, T. (1991): Synergistic enhancement of glutathione S-transferase placental form-positive hepatic foci development in diethylnitrosamine-treated rats by combined administration of five heterocyclic amines at low doses. Jpn. J. Cancer Res., **82**, 1378-1384.

Hirata, A., Tsukamoto, T., Sakai, H., Takasu, S., Ban, H., Imai, T., Totsuka, Y., Nishigaki, R., Wakabayashi, K., Yanai, T., Masegi, T. and Tatematsu, M. (2008): Carcinogenic risk of heterocyclic amines in combination - assessment with a liver initiation model. Food Chem. Toxicol., **46**, 2003-2009.

Hirose, M., Mutai, M., Takahashi, S., Yamada, M., Fukushima, S. and Ito, N. (1991): Effects of phenolic antioxidants in low dose combination on forestomach carcinogenesis in rats pretreated with N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res., **51**, 824-827.

Hoffman, B. and Liebermann, D.A. (1998): The proto-oncogene c-myc and apoptosis. Oncogene, **17**, 3351-3357.

Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U. and Speed, T.P. (2003): Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, **4**, 249-264.

Ito, N., Tamano, S. and Shirai, T. (2003): A medium-term rat liver bioassay for rapid *in vivo* detection of carcinogenic potential of chemicals. Cancer Sci., **94**, 3-8.

Kato, R. and Yamazoe, Y. (1987): Metabolic activation and covalent binding to nucleic acids of carcinogenic heterocyclic amines from cooked foods and amino acid pyrolysates. Jpn. J. Cancer Res., **78**, 297-311.

Kedika, R.R., Souza, R.F. and Spechler, S.J. (2009): Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig. Dis. Sci., **54**, 2312-2317.

Klaunig, J.E., Xu, Y., Isenberg, J.S., Bachowski, S., Kolaja, K.L., Jiang, J., Stevenson, D.E. and Walborg, E.F.Jr. (1998): The role of oxidative stress in chemical carcinogenesis. Environ. Health Perspect., **106, Suppl. 1**, 289-295.

Kociba, R.J., Keyes, D.G., Beyer, J.E., Carreon, R.M., Wade, C.E., Dittenber, D.A., Kalnins, R.P., Frauson, L.E., Park, C.N., Barnard, S.D., Hummel, R.A. and Humiston, C.G. (1978): Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol., **46**, 279-303.

Köhle, C. and Bock, K.W. (2007): Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem. Pharmacol., **73**, 1853-1862.

Kuribayashi, M., Asamoto, M., Suzuki, S., Hokaiwado, N., Ogawa, K. and Shirai, T. (2006): Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) rat hepatocarcinogenesis by caffeine, a CYP1A2 inducer, points to complex counteracting influences. Cancer Lett., **232**, 289-299.

Kuwata, K., Shibutani, M., Hayashi, H., Shimamoto, K., Hayashi, S.M., Suzuki, K. and Mitsumori K. (2011): Concomitant apoptosis and regeneration of liver cells as a mechanism of liver-tumor promotion by β-naphthoflavone involving TNFα-signaling due to oxidative cellular stress in rats. Toxicology, **283**, 8-17.

Lee, D.Y., Jung, Y.S., Kim, Y.C., Kim, S.Y. and Lee, M.G. (2009): Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding. Biopharm. Drug Dispos., **30**, 107-116.

Livak, K.J. and Schmittgen, T.D. (2001): Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods., **25**, 402-408.

Lynch, A.M., Knize, M.G., Boobis, A.R., Gooderham, N.J., Davies, D.S. and Murray, S. (1992): Intra- and interindividual variability in systemic exposure in humans to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, carcinogens present in cooked beef. Cancer Res., **52**, 6216-6223.

Ma, Q. and Lu, A.Y. (2007): CYP1A induction and human risk assessment: an evolving tale of *in vitro* and *in vivo* studies. Drug Metab. Dispos., **35**, 1009-1016.